Clinical Trial Update: Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a personalized antisense oligonucleotide for CHCHD10-related amyotrophic lateral sclerosis, covering Phase 1/Phase 2 investigations wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Personalized antisense oligonucleotide (CHCHD10 ALS) (antisense oligonucleotide targeting CHCHD10)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING